Loading ...
Sorry, an error occurred while loading the content.

PharmiWeb: InterMune's hepatitis strategy gets the right response

Expand Messages
  • Shshonee (Alley)
    InterMune s hepatitis strategy gets the right response 11 Feb 05 PharmiWeb Fri, 11 Feb 2005 5:18 AM PST A significant rise in sales of InterMune s hepatitis
    Message 1 of 1 , Feb 12, 2005
    • 0 Attachment
      InterMune's hepatitis strategy gets the right response
      11 Feb 05
      PharmiWeb Fri, 11 Feb 2005 5:18 AM PST
      A significant rise in sales of InterMune's hepatitis drug Infergen, from $9.3 million in 2003 to $22.3 million in 2004, is the result of the company's focus on marketing Infergen to HCV non-responders. In targeting this vital patient sub-group, InterMune could gain a useful head start in an area of hepatitis treatment that is set to become fiercely competitive in the years ahead.

      http://www.pharmiweb.com/features/feature.asp?ROW_ID=562

      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.